Shopping Cart 0
Cart Subtotal
USD 0

Intellipharmaceutics International Inc (IPCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Intellipharmaceutics International Inc (Intellipharmaceutics) is a pharmaceutical company that researches, develops, manufactures, and commercializes novel and generic targeted oral solid dosage pharmaceuticals. The company develops its controlled-release and targeted-release oral solid dosage drugs based on its proprietary technology, Hypermatrix, a multidimensional controlled-release drug delivery platform. Its products and product candidates are used for the treatment of various indications, including neuropathic pain, attention deficit hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, major depressive disorder, hypertension, type 2 diabetes, and chronic angina. It offers a comprehensive range of services, including pre-formulation studies, design, and development through to regulatory approval. Intellipharmaceutics' is headquartered in Toronto, Ontario, Canada.

Intellipharmaceutics International Inc (IPCI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 11

Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12

Equity Offering 13

Intellipharmaceutics Raises USD14.3 Million in Public Offering of Shares and Warrants 13

Intellipharmaceutics Raises USD1.8 Million in Private Placement of Shares 15

Intellipharmaceutics Raises USD3.5 Million in Private Placement of Shares and Warrants 16

Intellipharmaceutics Raises USD4 Million in Private Placement of Shares 17

Intellipharmaceutics International to Raise up to USD4 Million in Public Offering of Shares 19

Intellipharmaceutics International Raises USD5.2 Million in Public Offering of Units 20

Intellipharmaceutics International Announces Public Offering Of Shares For Up To USD 17 Million 22

Intellipharmaceutics International Completes Public Offering Of Units For USD 3 Million 23

Intellipharmaceutics International Completes Private Placement Of Units For USD 3 Million 24

Intellipharmaceutics International Completes Public Offering Of Common Stock For USD 5 Million 25

Debt Offering 27

Intellipharmaceutics Raises USD0.5 Million in Private Placement of 10% Debenture Due 2030 27

Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For USD 1.5 Million 28

Intellipharmaceutics International Inc-Key Competitors 29

Intellipharmaceutics International Inc-Key Employees 30

Intellipharmaceutics International Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Oct 15, 2018: Intellipharmaceutics announces third quarter 2018 results 32

Jul 16, 2018: Intellipharmaceutics reports second quarter 2018 results 35

Apr 16, 2018: Intellipharmaceutics Reports First Quarter 2018 Results 38

Oct 10, 2017: Intellipharmaceutics Announces Third Quarter 2017 Results 41

Jul 11, 2017: Intellipharmaceutics Announces Second Quarter 2017 Results 43

Apr 11, 2017: Intellipharmaceutics Announces First Quarter 2017 Results 45

Feb 10, 2017: Intellipharmaceutics Announces 2016 Year End Results 48

Corporate Communications 51

Nov 05, 2018: Intellipharmaceutics: Resignation of Chief Financial Officer 51

Jun 08, 2018: Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ 52

Apr 27, 2018: Intellipharmaceutics Files Appeal to Nasdaq Delisting Determination 53

Sep 01, 2017: Intellipharmaceutics Appoints New Chief Financial Officer 54

Aug 08, 2017: Intellipharmaceutics Announces Resignation of CFO 55

Legal and Regulatory 56

May 26, 2017: Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement 56

Product News 57

09/05/2017: Intellipharmaceutics Provides Operational Update 57

07/31/2017: Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit 59

05/08/2018: Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER 60

Product Approvals 61

Feb 09, 2018: Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program 61

Sep 25, 2017: Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista NDA 62

Jul 26, 2017: Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 63

Jun 30, 2017: Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 64

Feb 02, 2017: Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 65

Other Significant Developments 66

Jan 24, 2018: Intellipharmaceutics Provides Operational Update 66

Mar 16, 2017: Intellipharmaceutics Announces TSX Trading Symbol Change to "IPCI" 69

Appendix 70

Methodology 70

About GlobalData 70

Contact Us 70

Disclaimer 70


List Of Figure

List of Figures

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Intellipharmaceutics International Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 11

Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12

Intellipharmaceutics Raises USD14.3 Million in Public Offering of Shares and Warrants 13

Intellipharmaceutics Raises USD1.8 Million in Private Placement of Shares 15

Intellipharmaceutics Raises USD3.5 Million in Private Placement of Shares and Warrants 16

Intellipharmaceutics Raises USD4 Million in Private Placement of Shares 17

Intellipharmaceutics International to Raise up to USD4 Million in Public Offering of Shares 19

Intellipharmaceutics International Raises USD5.2 Million in Public Offering of Units 20

Intellipharmaceutics International Announces Public Offering Of Shares For Up To USD 17 Million 22

Intellipharmaceutics International Completes Public Offering Of Units For USD 3 Million 23

Intellipharmaceutics International Completes Private Placement Of Units For USD 3 Million 24

Intellipharmaceutics International Completes Public Offering Of Common Stock For USD 5 Million 25

Intellipharmaceutics Raises USD0.5 Million in Private Placement of 10% Debenture Due 2030 27

Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For USD 1.5 Million 28

Intellipharmaceutics International Inc, Key Competitors 29

Intellipharmaceutics International Inc, Key Employees 30

Intellipharmaceutics International Inc, Subsidiaries 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Intellipharmaceutics International Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Intellipharmaceutics International Inc (Intellipharmaceutics) is a pharmaceutical company that researches, develops, manufactures, and commercializes novel and generic targeted oral solid dosage pharmaceuticals. The company develops its controlled-release and targeted-release oral solid dosage drugs based on its proprietary technology, Hypermatrix, a multidimensional controlled-release drug delivery platform. Its products and product candidates are used for the treatment of various indications, including neuropathic pain, attention deficit hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, major depressive disorder, hypertension, type 2 diabetes, and chronic angina. It offers a comprehensive range of services, including pre-formulation studies, design, and development through to regulatory approval. Intellipharmaceutics' is headquartered in Toronto, Ontario, Canada.

Intellipharmaceutics International Inc (IPCI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 11

Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12

Equity Offering 13

Intellipharmaceutics Raises USD14.3 Million in Public Offering of Shares and Warrants 13

Intellipharmaceutics Raises USD1.8 Million in Private Placement of Shares 15

Intellipharmaceutics Raises USD3.5 Million in Private Placement of Shares and Warrants 16

Intellipharmaceutics Raises USD4 Million in Private Placement of Shares 17

Intellipharmaceutics International to Raise up to USD4 Million in Public Offering of Shares 19

Intellipharmaceutics International Raises USD5.2 Million in Public Offering of Units 20

Intellipharmaceutics International Announces Public Offering Of Shares For Up To USD 17 Million 22

Intellipharmaceutics International Completes Public Offering Of Units For USD 3 Million 23

Intellipharmaceutics International Completes Private Placement Of Units For USD 3 Million 24

Intellipharmaceutics International Completes Public Offering Of Common Stock For USD 5 Million 25

Debt Offering 27

Intellipharmaceutics Raises USD0.5 Million in Private Placement of 10% Debenture Due 2030 27

Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For USD 1.5 Million 28

Intellipharmaceutics International Inc-Key Competitors 29

Intellipharmaceutics International Inc-Key Employees 30

Intellipharmaceutics International Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Oct 15, 2018: Intellipharmaceutics announces third quarter 2018 results 32

Jul 16, 2018: Intellipharmaceutics reports second quarter 2018 results 35

Apr 16, 2018: Intellipharmaceutics Reports First Quarter 2018 Results 38

Oct 10, 2017: Intellipharmaceutics Announces Third Quarter 2017 Results 41

Jul 11, 2017: Intellipharmaceutics Announces Second Quarter 2017 Results 43

Apr 11, 2017: Intellipharmaceutics Announces First Quarter 2017 Results 45

Feb 10, 2017: Intellipharmaceutics Announces 2016 Year End Results 48

Corporate Communications 51

Nov 05, 2018: Intellipharmaceutics: Resignation of Chief Financial Officer 51

Jun 08, 2018: Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ 52

Apr 27, 2018: Intellipharmaceutics Files Appeal to Nasdaq Delisting Determination 53

Sep 01, 2017: Intellipharmaceutics Appoints New Chief Financial Officer 54

Aug 08, 2017: Intellipharmaceutics Announces Resignation of CFO 55

Legal and Regulatory 56

May 26, 2017: Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement 56

Product News 57

09/05/2017: Intellipharmaceutics Provides Operational Update 57

07/31/2017: Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit 59

05/08/2018: Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER 60

Product Approvals 61

Feb 09, 2018: Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program 61

Sep 25, 2017: Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista NDA 62

Jul 26, 2017: Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 63

Jun 30, 2017: Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 64

Feb 02, 2017: Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain 65

Other Significant Developments 66

Jan 24, 2018: Intellipharmaceutics Provides Operational Update 66

Mar 16, 2017: Intellipharmaceutics Announces TSX Trading Symbol Change to "IPCI" 69

Appendix 70

Methodology 70

About GlobalData 70

Contact Us 70

Disclaimer 70


List Of Figure

List of Figures

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Intellipharmaceutics International Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Intellipharmaceutics International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 11

Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 12

Intellipharmaceutics Raises USD14.3 Million in Public Offering of Shares and Warrants 13

Intellipharmaceutics Raises USD1.8 Million in Private Placement of Shares 15

Intellipharmaceutics Raises USD3.5 Million in Private Placement of Shares and Warrants 16

Intellipharmaceutics Raises USD4 Million in Private Placement of Shares 17

Intellipharmaceutics International to Raise up to USD4 Million in Public Offering of Shares 19

Intellipharmaceutics International Raises USD5.2 Million in Public Offering of Units 20

Intellipharmaceutics International Announces Public Offering Of Shares For Up To USD 17 Million 22

Intellipharmaceutics International Completes Public Offering Of Units For USD 3 Million 23

Intellipharmaceutics International Completes Private Placement Of Units For USD 3 Million 24

Intellipharmaceutics International Completes Public Offering Of Common Stock For USD 5 Million 25

Intellipharmaceutics Raises USD0.5 Million in Private Placement of 10% Debenture Due 2030 27

Intellipharmaceutics International Completes Private Placement Of Debentures Due 2015 For USD 1.5 Million 28

Intellipharmaceutics International Inc, Key Competitors 29

Intellipharmaceutics International Inc, Key Employees 30

Intellipharmaceutics International Inc, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Intellipharmaceutics International Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.